As all sides prepare for a milestone case in the battle over rights to CRISPR/Cas9, LSIPR’s Rory O’Neill finds the CEO of ERS Genomics in a positive mood.
As lawyers and industry prepare for a possible no-deal Brexit, the uncertainty surrounding its impact is palpable, as LSIPR’s Saman Javed discovers.
LSIPR’s Sarah Morgan investigates the current state of play of M&A in the sector and predicts the next year of activity.
In-house counsel face daily challenges when managing and maintaining their IP portfolios. LSIPR asked two in-house counsel for the biggest challenges they face when managing and maintaining their IP portfolios. Here are the five things we learned.
While providing benefits to Mexico’s biologics system, the USMCA may also increase costs for citizens, argues Margarita Guerrero Gonzalez of Uhthoff, Gomez Vega & Uhthoff.
A tie-up between four leading pharmaceutical companies, the UK government and a health charity has created the world’s largest genetic research project. LSIPR’s Rory O’Neill looks at a new frontier for life sciences.
An intervention by Russia’s IP ombudsman seeks to solve the validity issue over secondary patents, but is it needed, asks Maxim Sobolev of Rouse.
There is no doubting the importance of next year’s CRISPR appeal, but any conclusions about the parties’ prior art have consequences for elsewhere too, say Catherine Coombes and Emma Longland of HGF.
The Actavis v ICOS UK Supreme Court judgment was a bitter pill to swallow, but is it really the end of dosage patents? Richard Wells and Stephanie Pilkington of Potter Clarkson review the situation.
Filing a divisional patent application in Brazil needs a keen understanding of the process and flexibility in the system, as Kene Gallois and Luis Felipe Maciel da Silva of Daniel Law explain.